EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

From genomics to clinic: Guiding venetoclax-based therapy in AML via molecular determinants and risk models

Min Dai, Wei Li, Ruinan Jia, Yiping Hao, Wěi Li, Ying Zhou, Chunyan Ji, Jingjing Ye, Min Ji

Therapeutic Advances in Medical Oncology · 2026-11 · 18

DOI: 10.1177/17588359261499219 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 06.11.2026. Verfasst von Min Dai und 8 weiteren Autor:innen. Die Arbeit nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Shandong Province, Taishan Scholar Project of Shandong Province, National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The selective BCL-2 inhibitor venetoclax (VEN) combined with hypomethylating agents (HMAs) has redefined frontline therapy for older or unfit patients with acute myeloid leukemia (AML), achieving superior response rates and survival compared with HMA monotherapy. However, long-term outcomes remain heterogeneous and are largely shaped by the underlying molecular landscape. Current evidence indicates that the efficacy of VEN is dictated by distinct apoptotic dependencies, with some molecular subtypes exhibiting marked BCL-2 dependence, whereas others preferentially rely on survival pathways mediated by MCL-1 and BCL-xL. Contemporary risk stratification for lower-intensity therapy (LIT), exemplified by the European LeukemiaNet (ELN) 2024 classification, centers on TP53, NPM1, IDH1/2, FLT3-ITD, and RAS mutations. These molecular insights have driven the development of rational combination therapies incorporating mutation-specific inhibitors, novel epigenetic and immune-based agents. Treatment response may change over time as resistant subclones emerge and expand under therapeutic pressure, supporting the need for serial molecular and measurable residual disease (MRD) assessment. Integrating baseline molecular profiling with dynamic monitoring may guide timely treatment adaptation, including the incorporation of targeted therapies and consideration of allogeneic hematopoietic stem cell transplantation. This review summarizes the biological basis of VEN response, molecular risk models, and clinical evidence across molecular subtypes, providing a clinically oriented framework for molecularly guided treatment and identifying priorities for future research.

Förderung

  • Natural Science Foundation of Shandong Province
  • Taishan Scholar Project of Shandong Province
  • National Natural Science Foundation of China

Zitieren

APA

Dai, M., Li, W., Jia, R., Hao, Y., Li, W., Zhou, Y., Ji, C., Ye, J., & Ji, M. (2026). From genomics to clinic: Guiding venetoclax-based therapy in AML via molecular determinants and risk models. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261499219

Vancouver

Dai M, Li W, Jia R, Hao Y, Li W, Zhou Y, et al. From genomics to clinic: Guiding venetoclax-based therapy in AML via molecular determinants and risk models. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261499219

BibTeX
@article{Dai2026,
  author = {Dai, Min and Li, Wei and Jia, Ruinan and Hao, Yiping and Li, Wěi and Zhou, Ying and Ji, Chunyan and Ye, Jingjing and Ji, Min},
  title = {From genomics to clinic: Guiding venetoclax-based therapy in AML via molecular determinants and risk models},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359261499219}
}
Kostenlos starten →